Effectiveness and safety of monoclonal antibodies against amyloid-beta <i>vis-à-vis</i> placebo in mild or moderate Alzheimer's disease.

Front Neurol · 2023 · PMC10050585 · PMID 37006475

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

in a multicenter, randomized, placebo-controlled trial demonstrated a marginally significant increase in MMSE scores in favor of donepezil ( 51 ), and contrastingly, Rinne et al. found that bapineuzumab exerted an unfavorable effect on MMSE scores ( 21 ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.